BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. F1000Res 2020;9:609. [PMID: 32934806 DOI: 10.12688/f1000research.23996.2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdelkarem FM, Nafady AM, Allam AE, Mostafa MAH, Al Haidari RA, Hassan HA, Zaki MEA, Assaf HK, Kamel MR, Zidan SAH, Elsayed AM, Shimizu K. A Comprehensive In Silico Study of New Metabolites from Heteroxenia fuscescens with SARS-CoV-2 Inhibitory Activity. Molecules 2022;27:7369. [DOI: 10.3390/molecules27217369] [Reference Citation Analysis]
2 Esteves E, Mendes VM, Manadas B, Lopes R, Bernardino L, Correia MJ, Barros M, Esteves AC, Rosa N. COVID-19 Salivary Protein Profile: Unravelling Molecular Aspects of SARS-CoV-2 Infection. JCM 2022;11:5571. [DOI: 10.3390/jcm11195571] [Reference Citation Analysis]
3 Fuzo CA, Martins RB, Fraga-Silva TFC, Amstalden MK, Canassa De Leo T, Souza JP, Lima TM, Faccioli LH, Okamoto DN, Juliano MA, França SC, Juliano L, Bonato VLD, Arruda E, Dias-Baruffi M. Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion. Drug Dev Res 2022. [PMID: 35989498 DOI: 10.1002/ddr.21982] [Reference Citation Analysis]
4 Palmos AB, Millischer V, Menon DK, Nicholson TR, Taams LS, Michael B, Sunderland G, Griffiths MJ, Hübel C, Breen G; COVID Clinical Neuroscience Study Consortium. Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19. PLoS Genet 2022;18:e1010042. [PMID: 35239653 DOI: 10.1371/journal.pgen.1010042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 You H, Zhao Q, Dong M. The Key Genes Underlying Pathophysiology Correlation Between the Acute Myocardial Infarction and COVID-19. IJGM 2022;Volume 15:2479-90. [DOI: 10.2147/ijgm.s354885] [Reference Citation Analysis]
6 Peukert K, Steinhagen F, Fox M, Feuerborn C, Schulz S, Seeliger B, Schuss P, Schneider M, Frede S, Sauer A, Putensen C, Latz E, Wilhelm C, Bode C. Tetracycline ameliorates silica-induced pulmonary inflammation and fibrosis via inhibition of caspase-1. Respir Res 2022;23. [DOI: 10.1186/s12931-022-01937-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shen H, Zhang N, Liu Y, Yang X, He Y, Li Q, Shen X, Zhu Y, Yang Y. The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Front Pharmacol 2021;12:805535. [PMID: 35069217 DOI: 10.3389/fphar.2021.805535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Hasankhani A, Bahrami A, Sheybani N, Aria B, Hemati B, Fatehi F, Ghaem Maghami Farahani H, Javanmard G, Rezaee M, Kastelic JP, Barkema HW. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic. Front Immunol 2021;12:789317. [PMID: 34975885 DOI: 10.3389/fimmu.2021.789317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 He B, Garmire LX. ASGARD: A Single-cell Guided pipeline to Aid Repurposing of Drugs. ArXiv 2021:arXiv. [PMID: 34545335] [Reference Citation Analysis]
10 Pickard A, Calverley BC, Chang J, Garva R, Gago S, Lu Y, Kadler KE. Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. PLoS Pathog 2021;17:e1009840. [PMID: 34499689 DOI: 10.1371/journal.ppat.1009840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
11 Chen F, Shi Q, Pei F, Vogt A, Porritt RA, Garcia G Jr, Gomez AC, Cheng MH, Schurdak ME, Liu B, Chan SY, Arumugaswami V, Stern AM, Taylor DL, Arditi M, Bahar I. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. Mol Syst Biol 2021;17:e10239. [PMID: 34339582 DOI: 10.15252/msb.202110239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
12 Mosleh G, Badr P, Zaeri M, Mohagheghzadeh A. Potentials of Antitussive Traditional Persian Functional Foods for COVID-19 Therapy. Front Pharmacol 2021;12:624006. [PMID: 34335237 DOI: 10.3389/fphar.2021.624006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Yacouba A, Olowo-Okere A, Yunusa I. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. Ann Clin Microbiol Antimicrob 2021;20:37. [PMID: 34020659 DOI: 10.1186/s12941-021-00444-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
14 Fuzo CA, Martins RB, Fraga-silva TF, Amstalden MK, De Leo TC, Souza JP, Lima TM, Faccioli LH, França SC, Bonato VL, Arruda E, Dias-baruffi M. Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation.. [DOI: 10.1101/2021.04.20.439992] [Reference Citation Analysis]
15 Nain Z, Rana HK, Liò P, Islam SMS, Summers MA, Moni MA. Pathogenetic profiling of COVID-19 and SARS-like viruses. Brief Bioinform 2021;22:1175-96. [PMID: 32778874 DOI: 10.1093/bib/bbaa173] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 22.0] [Reference Citation Analysis]
16 Pickard A, Calverley BC, Chang J, Garva R, Lu Y, Kadler KE. Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. bioRxiv 2021:2021. [PMID: 33564760 DOI: 10.1101/2021.01.31.428851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Takahashi Y, Hayakawa A, Sano R, Fukuda H, Harada M, Kubo R, Okawa T, Kominato Y. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep 2021;11:3379. [PMID: 33564039 DOI: 10.1038/s41598-021-82970-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
18 Gironi LC, Damiani G, Zavattaro E, Pacifico A, Santus P, Pigatto PDM, Cremona O, Savoia P. Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses. Dermatol Ther 2021;34:e14694. [PMID: 33354849 DOI: 10.1111/dth.14694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
19 Khurana P, Gupta A, Sugadev R, Sharma YK, Varshney R, Ganju L, Kumar B. nSARS-Cov-2, pulmonary edema and thrombosis: possible molecular insights using miRNA-gene circuits in regulatory networks. ExRNA 2020;2:16. [PMID: 33209992 DOI: 10.1186/s41544-020-00057-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Gargouri M, Alzwi A, Abobaker A. Cyclin dependent kinase inhibitors as a new potential therapeutic option in management of COVID-19. Med Hypotheses 2021;146:110380. [PMID: 33213999 DOI: 10.1016/j.mehy.2020.110380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Barh D, Tiwari S, Weener ME, Azevedo V, Góes-Neto A, Gromiha MM, Ghosh P. Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19. Comput Biol Med 2020;126:104051. [PMID: 33131530 DOI: 10.1016/j.compbiomed.2020.104051] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 26.5] [Reference Citation Analysis]